Part of the problem is we dont have research on long-term impacts yet, nor is the drug available at such a scale that those impacts could be seen yet
In total, 9341 participants (6322 on previously or currently licensed weight management drugs and 3019 on non-drug therapies or placebo) were included
Treatment options are diverse, including injections, patches, gels, and pellets, offering flexibility and convenience for patients
The intake gives the clinician useful context: goals, history, medication use, symptoms, and prior treatment experience before any injectable GLP-1 option is considered
Rather, it acknowledges that the availability and use of so-called classic PEDs are increasing in the general population, particularly among recreational and sub-elite athletes, and increasingly also among female athletes, thereby creating a growing clinical reality for CV care